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Abstract
Spinocerebellar ataxia type-3 (SCA-3) is the most prevalent autosomal dominant inherited
ataxia. We recently found that the endocannabinoid system is altered in the post-mortem
cerebellum of SCA-3 patients, and similar results were also found in the cerebellar and
brainstem nuclei of a SCA-3 transgenic mouse model. Given that the neuropathology of
SCA-3 is not restricted to these two brain regions but rather, it is also evident in other struc-
tures (e.g., the basal ganglia), we studied the possible changes to endocannabinoid signal-
ing in the striatum of these transgenic mice. SCA-3 mutant mice suffer defects in motor
coordination, balance and they have an abnormal gait, reflecting a cerebellar/brainstem neu-
ropathology. However, they also show dystonia-like behavior (limb clasping) that may be
related to the malfunction/deterioration of specific neurons in the striatum. Indeed, we found
a loss of striatal projecting neurons in SCA-3 mutant mice, accompanied by a reduction in
glial glutamate transporters that could potentially aggravate excitotoxic damage. In terms of
endocannabinoid signaling, no changes in CB2 receptors were evident, yet an important
reduction in CB1 receptors was detected by qPCR and immunostaining. The reduction in
CB1 receptors was presumed to occur in striatal afferent and efferent neurons, also poten-
tially aggravating excitotoxicity. We also measured the endocannabinoid lipids in the stria-
tum and despite a marked increase in the FAAH enzyme in this area, no overall changes in
these lipids were found. Collectively, these studies confirm that the striatal endocannabinoid
system is altered in SCA-3 mutant mice, adding to the equivalent changes found in other
strongly affected CNS structures in this type of ataxia (i.e.: the cerebellum and brainstem).
These data open the way to search for drugs that might correct these changes.
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Introduction
Important changes in the endocannabinoid signaling system have been found in the CNS
structures affected in most acute and chronic neurodegenerative disorders ([1,2] for review).
Such changes have been interpreted in two ways. On the one hand, dysregulation of cannabi-
noid receptor type-1 (CB1) signaling has been associated with maladaptive responses that
eventually contribute to disease symptoms (e.g., bradykinesia, ataxia, choreic movements)
and/or to enhanced neuronal deterioration (e.g., heightened glutamate toxicity: [1,2]). Indeed,
the elevated activity of endocannabinoid hydrolyzing enzymes like fatty acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL) has been associated with such maladaptive
responses, provoking excessive degradation of endocannabinoids that dampens their prosurvi-
val properties ([2,3] for review). On the other hand, the up-regulation of cannabinoid receptor
type-2 (CB2), particularly in activated glial elements, produces an endogenous protective
response that helps limit the consequences of neurotoxic insults, mainly inflammatory events
but also oxidative stress and excitotoxicity, all of which operate in most neurodegenerative dis-
orders ([2,4,5] for review). A similar interpretation has been employed when considering the
massive generation of endocannabinoids under neurotoxic conditions in vitro and in vivo ([2]
for review).
In general, both dysregulation and endogenous protection are active in numerous neurode-
generative pathologies, both acute (e.g., stroke [6], brain trauma [7], spinal injury [8]) and
chronic progressive disorders (e.g., Alzheimer’s disease [9], Parkinson’s disease [10], Hunting-
ton’s chorea [11,12], amyotrophic lateral sclerosis [13,14] and others [2]). Such responses have
also been seen in autosomal-dominant spinocerebellar ataxias (SCAs; [15–17]), a group of
inherited neurodegenerative disorders that mainly affect the cerebellum and its afferent/effer-
ent structures, in which motor discoordination (“ataxia”) is the key symptom [18–21]. How-
ever, in most SCAs, and in particular SCA-3 or Machado-Joseph disease, the most prevalent of
these rare disorders ([22] for review), neuronal malfunction/degeneration also occurs in extra-
cerebellar structures like the brainstem, optic nerve, cortical areas and the basal ganglia ([23–
25] for review). This explains why patients develop a broad-spectrum of neurological abnor-
malities, including primary cerebellar symptoms (e.g., progressive loss of motor coordination
and abnormal gait: [24,26] for review) and non-cerebellar symptoms (e.g., muscle atrophy,
oculomotor impairment, spasticity, and extrapyramidal signs such as rigidity and dystonia:
[21,24,27] for review).
We recently found that endocannabinoid signaling appears to be dysregulated in the cere-
bellum SCA patients (including SCA-3), with important alterations to CB1 and CB2 receptors
[15], and to FAAH and MAGL enzymes in post-mortem tissue [16]. Such alterations were also
found recently in a transgenic mouse model of SCA-3 [17], which reproduces many of the
neurological and neuropathological signs of the disease [28]. This earlier study [17] concen-
trated on two key CNS structures (cerebellum and brainstem) closely related to the classic
symptoms (motor incoordination, imbalance, gait anomalies) and neuropathological lesions
(the loss of specific neuronal subpopulations in the dentate nucleus, Purkinje layer and pontine
nuclei) observed in SCA-3 [25,26,29,30]. Hence, the pharmacological correction of such
changes in endocannabinoid signaling may represent a promising therapeutic option for this
disease. However, the neuropathology of SCA-3 is not restricted to these two CNS areas and it
is also affects other important structures like the basal ganglia, which explains the occurrence
of extrapyramidal defects in SCA-3 patients [31] and in our SCA-3 transgenic mouse model
(e.g., dystonia, rigidity: [17]). Therefore, the goal of this follow-up study was to investigate the
changes to the endocannabinoid signaling system in the striatum of these transgenic mice
using different biochemical and histological approaches.
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Materials and methods
Animals and sampling
All experiments were carried out on pCMVMJD135 transgenic mice and their wild-type litter-
mates [28]. Offspring were genotyped to detect those that carried the transgene containing the
ataxin-3 mutation (around 135Q), as described previously [28]. All animals were housed
under a controlled photoperiod (08:00–20:00 lights on) and temperature (22 ± 1˚C), with free
access to standard food and water. All the experiments were conducted in accordance with
local and European legislation (directive 2010/63/EU), and following the principles of the
ARRIVE guidelines. The protocols were also approved by the animal experimentation com-
mittee at our university (ref. CEA-UCM 56/2012).
We used non-transgenic and pCMVMJD135Q transgenic male mice for longitudinal stud-
ies to initially characterize the appearance of striatal malfunctioning/degeneration at the bio-
chemical and histological levels. Subsequently possible alterations in the endocannabinoid
signaling were evaluated in this structure. These animals were characterized 7–55 weeks after
birth [17], detecting dystonic-like behavior (limb clasping) and establishing three different dis-
ease states: (i) an early symptomatic stage, up to 16 weeks after birth, characterized by a loss of
muscle strength in the hanging wire test [28]; (ii) a stable symptomatic stage, up to 32 weeks
after birth, involving impaired performance on the balance beam and rotarod indicative of
impaired balance and motor coordination [28]; and (iii) an advanced stage, up to 56 weeks
after birth, in which marked deficiencies in gait and dystonia were reflected by the animal
performance in footprinting tests and through their clasping behavior, respectively [17].
Groups of SCA-3 transgenic and wild-type mice of these three ages were perfused transcar-
dially with saline followed by fresh 4% paraformaldehyde in 0.1M phosphate buffered saline
(PBS, pH 7.4), and their brain was collected and post-fixed for one day at 4˚C. The tissue was
then cryoprotected by immersion in a 30% sucrose solution for a further day, and finally stored
at -80˚C for Nissl staining and immunohistochemical analysis. The striatum was dissected out
of brain of other mice and rapidly frozen on dry ice for subsequent biochemical analysis
(qRT-PCR and western blotting), as well as to analyze the endocannabinoid concentrations. In
all of the experiments, 6–8 male mice were used per experimental group.
Biochemical analyses
Real time qRT-PCR analysis. Total RNA was extracted from the striatum using the Sure-
Prep™ RNA/Protein Purification kit (Fisher BioReagents, Fair Lawn, NJ, USA) and it was
quantified by spectrometry at 260 nm. The RNA purity was evaluated through the absorbance
ratio at 260 and 280 nm, whereas its integrity was confirmed in agarose gels. Genomic DNA
was removed enzymatically and single-stranded complementary DNA was synthesized from
1 μg of total RNA using a commercial kit (Rneasy Mini Quantitect Reverse Transcription, Qia-
gen, Izasa, Madrid, Spain). The cDNAs were amplified by quantitative real-time PCR using
TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA: see Table 1),
using GADPH as an endogenous control gene for normalization. The PCR assays were per-
formed using the 7300 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) and the threshold cycle (Ct) was calculated using the instrument’s software (7300 Fast
System, Applied Biosystems, Foster City, CA, USA).
Western blotting. Purified protein fractions were isolated using the SurePrep™ RNA/Pro-
tein Purification kit (Fisher BioReagents, Fair Lawn, NJ, USA) and aliquots of protein (20 μg)
were boiled for 5 min in Laemmli SDS loading buffer (10% glycerol, 5% SDS, 5% β-mercap-
toethanol, 0.01% bromophenol blue and 125 mM TRIS-HCl [pH 6.8]) prior to loading onto a
Striatal endocannabinoid signaling in SCA-3
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12% acrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA). The proteins were transferred
to a PVDF membrane (Immobilon-P, Millipore, Bedford, MA, USA) using a mini Trans-Blot
Electrophoretic transfer cell (Bio-Rad Laboratories, Hercules, CA, USA), which were then
blocked with 5% non-fat milk. The membranes were probed overnight at 4˚C with the anti-
FAAH antibody (see Table 2) and then for 2 hours at room temperature with an ECL™ Horse-
radish Peroxidase-linked whole secondary antibody (GE Healthcare UK Limited, Bucking-
hamshire, UK) diluted 1:5000. Reactive bands were detected by chemiluminescence with the
Amersham™ ECL™ Prime Western Blotting Detection Reagent (GE Healthcare UK Limited,
Buckinghamshire, UK) and the membranes were analyzed on a ChemiDoc station with Quan-
tity one software (Bio-Rad Laboratories, Madrid, Spain). The optical density of the specific
protein bands were assessed relative to the housekeeping protein GAPDH, and they were nor-
malized to the controls.
LC/MS analysis for endocannabinoid levels. The amounts of endocannabinoids, and
their related N-acylethanolamines and 2-acylglycerols, were determined by liquid chromatog-
raphy-atmospheric pressure chemical ionization-mass spectrometry (LC/MS; 1100 LC-MSD,
SL model; Agilent Technologies Inc., Wilmington, DE, USA), incorporating slight modifica-
tions to a previously described protocol [32]. Tissue samples were weighed and placed into
borosilicate glass tubes containing 2 ml of acetonitrile with 84 pmol of [2H8]AEA and 186
pmol of [2H8]2-AG (Cayman Chemical, Ann Arbor, MI, USA). The tissues were homogenized
with a glass rod and sonicated for 60 min. The samples were incubated overnight at -20˚C to
precipitate the proteins, they were centrifuged at 1,500g for 3 min, and the supernatant was
Table 1. TaqMan probes used.
Gene Name TaqMan Ref.
CB1 receptor Mm00432621_s1
CB2 receptor Mm00438286_m1
FAAH Mm00515684_m1
MAGL Mm00449274_m1
DAGL Mm00813830_m1
NAPE-PLD Mm00724596_m1
calbindin Mm00486647_m1
NSE Mm00469062_m1
BDNF Mm01334042_m1
DARPP32 Mm00454892_m1
IL-1β Mm00434228_m1
TNF-α Mm99999068_m1
GLAST Mm00600697_m1
GLT-1 Mm00441457_m1
GAPDH Mm99999915_g1
https://doi.org/10.1371/journal.pone.0176521.t001
Table 2. List of antibodies used in western blotting or immunohistochemical analyses (WB: Western blotting; IHC: Immunohistochemistry).
ANTIBODY DILUTION (IHC) DILUTION (WB) CLASS MANUFACTURER
anti-CB1: Rb-Af380 1:500 Polyclonal Frontier Institute, Hokkaido, Japan
anti-FAAH:sc-26427 1:200 1:200 Polyclonal Santa Cruz Biotechnology, CA, USA
anti-GAPDH:G8795 1:5000 Monoclonal Sigma Chem., Madrid, Spain
anti-GFAP:Z0334 1:500 Polyclonal DakoCytomation, Glostrup, Denmark
anti-Iba1:019–19741 1:300 Polyclonal Wako, Osaka, Japan
https://doi.org/10.1371/journal.pone.0176521.t002
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removed to a new glass tube and evaporated to dryness under nitrogen. The samples were then
resuspended in methanol (300 μl) to recapture any lipids adhering to the glass tube and dried
again. Finally, the lipid extracts were suspended in 30 μl of methanol, 5 μl of which was used
for the LC/MS analysis. Each sample was separated on a reverse-phase C18 column (Kromasil,
250 × 2 mm, 5-μm diameter) using mobile phase A (deionized water with 1 mM ammonium
acetate and 0.005% acetic acid) and mobile phase B (methanol with 1 mM ammonium acetate
and 0.005% acetic acid). The samples were eluted at a flow rate of 300 μl/min under a linear
gradient, with the percentage of solvent B increasing linearly from 85% to 100% over 25 min
and maintaining 100% solvent B for 10 min. Over the next 10 min, solvent B decreased linearly
from 100 to 85% and it was held at 85% for an additional 10 min.
MS detection was carried out in the selected ion monitoring mode using m/z values to
detect [2H8]AEA (m/z 356), AEA (m/z 348), [
2H8]2-AG and 1(3)-AG (m/z 387), 2-AG and 1
(3)-AG (m/z 379), PEA (m/z 299), OEA (m/z 326) and 2-OG and 1(3)-OG (m/z 357). As
2-AG and 2-OG are usually observed as doublets due to isomerization to the 1,3 form during
extraction, the area of both peaks was combined to yield the total 2-AG or 2-OG. To calibrate
the system, standard curves for the AEA, PEA, OEA, 2-AG and 2-OG (Cayman Chemical,
Ann Arbor, MI, USA) were used. Each endocannabinoid concentration in the different sam-
ples was calculated by comparison with the corresponding deuterated internal standard: [2H8]
AEA to calculate the AEA, PEA and OEA levels; and [2H8]2-AG in the case of 2-AG and
2-OG. The amounts of endocannabinoids and related N-acylethanolamines and 2-acylglycer-
ols were normalized to the wet tissue weight and expressed as a percentages of the controls.
Histological procedures
Tissue slices. Sagittal cryostat sections of fixed brains (30 μm thick) were collected on gel-
atin-coated slides, and either Nissl-stained or used for immunohistochemistry.
Nissl staining. Frozen sagittal brain sections were incubated with 0.1% methylene blue
for 5 min and washed with distilled water. The sections were then dehydrated, sealed and cov-
erslipped with non-aqueous mounting medium. A Leica DMRB microscope (Leica, Wetzlar,
Germany) and a DFC300FX camera (Leica) were used to study and photograph the tissue,
respectively. To count the number of Nissl-stained cells, high resolution photomicrographs
were taken with a 20x objective under the same conditions of light, brightness and contrast.
Four images from at least 3 sections per animal were analyzed to establish the mean of all the
animals studied from each group. The data are expressed relative to the wild-type animals.
Immunohistochemistry. Sections were preincubated for 20 min in 0.1M PBS with 0.1%
Triton X-100 [pH 7.4], and endogenous peroxidase activity was blocked by incubating them
for 1 hour at room temperature in blocking solution (Dako Cytomation, Glostrup, Denmark).
After incubation overnight at 4˚C with the corresponding primary antibody (see Table 2)
diluted in 0.1M PBS with 0.01% Triton X-100 [pH 7.4], the sections were washed in 0.1M PBS
and incubated for 2 hours at room temperature with the appropriate biotin-conjugated anti-
goat or anti-rabbit secondary antibodies (1:200; Vector Laboratories, Burlingame, CA, USA).
An avidin-biotin complex (Vectastain1 Elite ABC kit; Vector Laboratories, Burlingame, CA,
USA) and a DAB substrate–chromogen system (Dako Cytomation, Glostrup, Denmark) were
used to obtain a visible reaction product. Negative control sections were obtained using the
same protocol with the omission of the primary antibody. All sections for each immunohisto-
chemical procedure were processed at the same time and under the same conditions. The sec-
tions were observed and photographed on a Leica DMRB microscope and with a Leica
DFC300FX camera (Leica, Wetzlar, Germany). To quantify the immunoreactivity, the NIH
Image Processing and Analysis software was used (ImageJ; NIH, Bethesda, MD, USA) on 4–5
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randomly selected sections. The tissue was visualized with 20x objective by researchers blind
to the experimental treatments and the data were expressed relative to the wild-type tissue.
Statistics
The data were assessed using the GraphPad software (version 5.0), applying an unpaired Stu-
dent’s t-test or two-way ANOVA for repeated measures followed by the Bonferroni test, as
required.
Results
Characterization of the striatal damage in SCA-3 transgenic mice
We recently described the progressive motor deterioration experienced by SCA-3 transgenic
mice, as evident in the hanging wire, balance beam and rotarod tests [17,28]. In these studies,
we also detected the presence of hindlimb clasping, a common marker of dystonia in mouse
models of neurological disorders (including certain cerebellar ataxias [21]) and an extremely
frequent response in SCA-3 mouse models [17,33]. Dystonia is an extrapyramidal sign often
related to basal ganglia malfunction [34,35]. Thus, we have attempted to find a neuropatholog-
ical basis for this response by analyzing the striatum of SCA-3 transgenic mice, a brain region
significantly altered in SCA-3 patients [21]. We first assessed different biochemical markers
that reflect either neuronal malfunction or neurodegeneration, combining qPCR with histo-
logical procedures to define neuronal loss or glial activation in this structure. Our qPCR stud-
ies revealed a marked reduction in the expression of the calbindin gene that appeared to
commence at 16 weeks but that was significantly weaker at 32 and 56 weeks (Fig 1A). A
Fig 1. Histological and biochemical analysis of neuronal damage in the striatum of SCA-3 transgenic
and wild-type mice. Panel A: A qPCR analysis of calbindin, neuron-specific enolase, BDNF and the striatal
neuronal marker DARPP-32 expression in the striatum of SCA-3 transgenic and wild-type mice of different
ages. Panel B: Nissl staining and neuron quantification in the striatum of SCA-3 transgenic and wild-type mice
56 weeks after birth (bar = 25 μm). Arrows indicate the presence of Nissl-stained cells with smaller cell bodies
in the SCA-3 transgenic mice. In all cases, the values are expressed as the mean ± SEM of more than 6
animals per group, assessing the data using a Student’s t-test: *p<0.05 versus wild-type animals.
https://doi.org/10.1371/journal.pone.0176521.g001
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decrease in DARPP32 expression was also seen at 56 weeks, a selective marker for striatal pro-
jection neurons, whereas other less-selective neuronal markers like NSE and BDNF did not
appear to be affected (Fig 1A). The number of Nissl-stained cells in the striatal parenchyma of
56 week-old SCA-3 transgenic mice was also lower than in wild-type animals, and the surviv-
ing Nissl-stained cells in these mutant mice generally had a smaller cell body (see arrows in Fig
1B). Collectively, these data confirmed the deterioration of striatal neurons, in particular pro-
jection neurons, in SCA-3 transgenic mice, as also described in other SCA-3 models [33].
These data were consistent with the atrophy of the striatum and its output nuclei (globus palli-
dus, substantia nigra) described in SCA-3 patients [31].
We also investigated the possible glial activation in this structure using Iba-1 immunostain-
ing to label microglial cells (Fig 2A). However, there were no significant differences in the
number of Iba-1 positive cells or the staining intensity between 56 week-old (Fig 2B) or youn-
ger (data not shown) SCA-3 transgenic and wild-type mice. Similarly no such changes were
evident in the expression of the proinflammatory cytokines IL-1β and TNF-α (Fig 2C). By con-
trast, the expression of glial glutamate transporters was significantly lower in the striatum of
SCA-3 transgenic mice, both that of GLT-1 (16, 32 and 56 weeks) and GLAST (32 and 56
weeks: Fig 2C). However, the reduction in glutamate transporters was not associated with
changes in GFAP immunostaining in the striatal parenchyma of SCA-3 transgenic mice rela-
tive to the wild-type animals (data not shown), a marker of astrocytes.
Analysis of the endocannabinoid signaling system in the striatum of
SCA-3 transgenic mice
We initially explored the changes in endocannabinoid signaling by studying CB1 receptor
expression by qPCR, detecting a significant reduction in 32 and 56 week-old SCA-3 transgenic
Fig 2. Histological and biochemical analysis of glial activation in the striatum of SCA-3 transgenic
and wild-type mice. Panels A and B: Immunostaining (representative microphotographs and their
quantification) for Iba-1 as a microglial marker in the striatum of 56 week-old SCA-3 transgenic and wild-type
mice (bar = 200 μm, 50 μm and 20 μm, respectively). Panel C: qPCR analysis of the proinflammatory
cytokines IL-1β and TNF-α, and of the glial glutamate transporters GLAST and GLT-1, in the striatum of SCA-
3 transgenic and wild-type mice at different ages. In all cases, the values are expressed as the mean ± SEM of
more than 6 animals per group, assessing the data using a Student’s t-test: *p<0.05, **p<0.01 versus wild-
type animals.
https://doi.org/10.1371/journal.pone.0176521.g002
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mice (Fig 3A). This reduction might be related to the loss of CB1 receptor-containing striatal
projection neurons in SCA-3 transgenic mice, the cell bodies of which are located in the stria-
tum (see above). Indeed, this response was similar to that described in Huntington’s disease,
another polyQ disorder in which the striatum is preferentially affected [36]. Accordingly, we
expected to find less CB1 receptor immunoreactivity in the cell bodies of striatal projection
neurons in SCA-3 transgenic mice. However, we were unable to label these cell bodies in either
SCA-3 transgenic or wild-type mice (Fig 3B), possibly because CB1 receptors localize predomi-
nantly to the terminals of neurons that arise in the globus pallidus and the substantia nigra,
and not significantly to their cell bodies [37]. Conversely, we did detect CB1 receptors in termi-
nals projecting to the striatum (see arrows in Fig 3B), almost certainly belonging to corticos-
triatal neurons [38]. Quantification of this immunolabeling indicated there were no changes in
young, 16 week-old SCA-3 transgenic and wild-type mice, although there was notable reduc-
tion of immunoreactivity in SCA-3 transgenic mice at 32 and 56 weeks of age (Fig 3C). This
reduction was not correlated with the reduction found in CB1 receptor mRNA in the striatum
(Fig 3A), as the cell bodies for these neurons are located in cortical areas.
We detected an increase in FAAH mRNA expression in the whole striatum at 32 and 56
weeks (Fig 4A), a change also seen in patients and animal models of Huntington’s disease
[36]. However, no such increase was seen in western blots (Fig 4B). FAAH immunostaining
Fig 3. Histological and biochemical analysis of the CB1 receptor in the striatum of SCA-3 transgenic
and wild-type mice. Panel A: qPCR analysis of the CB1 receptor in the striatum of SCA-3 transgenic and
wild-type mice at different stages of disease progression. Panels B and C: Immunostaining for the CB1
receptor in the striatum of SCA-3 transgenic and wild-type mice at different stages of disease progression
(bar = 50 μm and 10 μm, respectively). The arrows indicate the presence of CB1 receptor immunolabeling in
corticostriatal terminals. In all cases, the values are expressed as the mean ± SEM of more than 6 mice per
group, assessing the data using a Student’s t-test: *p<0.05, **p<0.01 versus wild-type animals.
https://doi.org/10.1371/journal.pone.0176521.g003
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demonstrated an intense signal in the cell bodies of striatal neurons (see arrows in Fig 4C),
although there were no apparent differences in the cellular and subcellular distribution
between SCA-3 transgenic and wild-type mice at 16, 32 and 56 weeks of age (Fig 4C). How-
ever, quantification of the immunostaining revealed elevated immunolabeling in SCA-3 trans-
genic mice at 32 weeks of age (Fig 4D), despite the deterioration of the striatal projection
neurons described above (Fig 1A). Thus, as surviving neurons may express more FAAH (Fig
4A), this change may only be evident at local levels as it was not seen in western blots of the
whole striatum (Fig 4B).
Lastly, no differences were detected between SCA-3 transgenic and wild-type mice when
other endocannabinoid genes were assessed at the three ages studied, including the CB2 recep-
tor, NAPE-PLD, DAGL and MAGL (Fig 5A–5D). We also measured anandamide and 2-AG,
as well as their related signaling lipids PEA, OEA and 2-OG, again failing to detect differences
between SCA-3 transgenic mice and wild-type animals at the ages studied (Fig 5E–5I).
Discussion
This study demonstrates that certain elements of the endocannabinoid signaling system (CB1
receptors, the FAAH enzyme) are altered in the striatum of SCA-3 transgenic mice, as previ-
ously found in other important brain structures affected in this type of ataxia (cerebellum and
brainstem [17]).
Fig 4. Histological and biochemical analysis of the FAAH enzyme in the striatum of SCA-3
transgenic and wild-type mice. Panels A and B: qPCR analysis and Western blot quantification (in a
representative blot) of the FAAH enzyme in the striatum of SCA-3 transgenic and wild-type mice at different
stages of disease progression. Panels C and D: Immunostaining for the FAAH enzyme in the striatum of
SCA-3 transgenic and wild-type mice at different stages of disease progression (bar = 50 μm). Arrows
indicate stronger immunolabeling in surviving striatal neurons of SCA-3 transgenic mice. In all cases, the
values are expressed as the mean ± SEM of more than 6 animals per group, assessing the data using a
Student’s t-test: *p<0.05, **p<0.01 versus wild-type animals.
https://doi.org/10.1371/journal.pone.0176521.g004
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The SCA-3 transgenic mice used in this study exhibited a broad-spectrum of motor anoma-
lies that are comparable to the clinical symptoms found in patients. These included basal
ganglia-related extrapyramidal signs like dystonia [17,28], which should a priori be the conse-
quence of the selective deterioration of striatal projecting neurons that are also affected in the
human pathology [24,25]. As in humans, neurodegeneration does not appear to be associated
with marked glial activation or inflammatory events [21]. Rather, early alterations to glial glu-
tamate transporters associate the degenerative process with elevated glutamate toxicity, consis-
tent with our earlier observations in the brainstem nuclei [17]. Such toxicity was also found in
other SCA-3 models [39] and it has been proposed to be the basis for the extension of neurode-
generation to extracerebellar structures in SCA-3 [20]. As such, the CMVMJD135 SCA-3
mouse model would appear to be useful for the study of extrapyramidal signs/basal ganglia
deterioration in the progression of SCA-3, including the contribution of the endocannabinoid
signaling system to this progression, the objective pursued herein.
Our goal was to determine whether endocannabinoid signaling is altered in the striatum of
CMVMJD135 mice, possibly contributing to disease progression. This is indeed the case, as
our findings are consistent with a possible reduction in CB1 receptor signaling with elevated
FAAH levels in this structure, both events that are compatible with enhanced excitotoxic dam-
age. The nature of such altered endocannabinoid signals is clearly dependent on the cellular
Fig 5. Biochemical analysis of endocannabinoid genes and proteins, and of related signaling lipids
in the striatum of SCA-3 transgenic and wild-type mice. Panels A-D: qPCR analysis of the CB2 receptor
and of the NAPE-PLD, DAGL and MAGL enzymes in the striatum of SCA-3 transgenic and wild-type mice
at different stages of disease progression. Panels E-I: LC-MS analysis of the levels of anandamide (AEA)
and its related congeners, palmitoylethanolamide (PEA) and oleylethanolamide (OEA), as well as
2-arachidonoylglycerol (2-AG) and its congener [2-oleylglycerol (2-OG), in the striatum of SCA-3 transgenic
and wild-type mice at different stages of disease progression. In all cases, the values are expressed as the
mean ± SEM of 5–6 subjects per group, assessing the data using a Student’s t-test.
https://doi.org/10.1371/journal.pone.0176521.g005
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context, as the changes were not exactly the same in the striatum as in the cerebellum and
brainstem [17]. In addition to contributing to disease progression, the changes in endocanna-
binoid signaling in SCA-3 transgenic mice may be associated with the appearance of specific
neurological symptoms like the loss of motor coordination observed in these mice. Such symp-
toms were previously related to the elevated CB1 receptor-mediated signaling in the Purkinje
cell layer, predominantly in terminals of the basket cells [17]. Along similar lines, the reduced
CB1 receptor signaling found in the striatum may be related to the dystonia (clasping behavior)
described in these mice [17], particularly given the relevance of the basal ganglia circuits in
controlling dystonic responses [34,35]. However, recent data related the onset of dystonia to
the malfunction of other CNS structures, including the cerebellum [40], making it possible if
this is also related to the altered endocannabinoid signals in the cerebellum.
Such alterations to CB1 receptor signaling could be pharmacologically corrected using
direct agonists of this receptor or even by elevating the endocannabinoid tone by inhibiting
endocannabinoid inactivation (e.g. FAAH/MAGL inhibition). Such an approach should atten-
uate dystonia, as documented in a few pharmacological studies on dystonic patients [41] or
experimental models [42]. While this may relieve these symptoms, our aim was to obtain a
more effective and sustained alleviation of these symptoms by controlling disease progression
through cannabinoid-based therapies [3]. In this sense, our data indicate that the activation
of CB1 receptors may also be beneficial to avoid the loss of striatal projection neurons, as
described previously in murine models of Huntington’s disease [36]. In both cases, alleviating
dystonia or preserving striatal neurons, the therapy aims to correct the changes in endocanna-
binoid signaling by enhancing CB1 receptor function, assuming that these changes represent a
maladaptive response that contributes to disease progression. This appears to be the case for
the elevated FAAH levels found in the striatum, which would also be a maladaptive response
possibly contributing to disease progression through excessive endocannabinoid degradation.
In this sense, it may be better to selectively inhibit the FAAH enzyme in order to enhance the
levels of endocannabinoids and their protective function. In both cases, enhancing CB1 recep-
tor signaling or inhibiting FAAH enzyme would address the changes in both targets that may
contribute to this pathology.
The neuroprotection elicited by cannabinoids may also involve an enhancement of specific
responses that represent adaptive mechanisms aimed at restoring neuronal integrity and
homeostasis in the face of neurotoxic insults [43]. We expect this may be the case of CB2 recep-
tor-mediated signaling, given that it is up-regulated in an attempt to preserve neurons against
inflammatory events in most neurodegenerative disorders [2,4], including SCAs when post-
mortem tissue from patients is studied [15]. However, we were unable to find any evidence of
such events in the striatum of these SCA-3 transgenic mice, as occurs in the cerebellum and
brainstem [17] where CB2 receptor levels also remain unaffected. We assume that the lack of a
CB2 receptor response may reflect the relatively limited glial reactivity found in the affected
CNS areas in this model [28].
Another adaptive response frequently elicited by endocannabinoid signaling in response to
damage is an elevation in the generation of endocannabinoids. This has been described for dif-
ferent chronic neurodegenerative disorders [1], yet as in the other CNS structures investigated
previously [17], we did not find elevated endocannabinoid levels in the striatum of SCA-3
transgenic mice. In fact, given the elevated FAAH immunostaining in specific striatal neurons
the expected local reduction of these signaling lipids was not evident in Western blots, most
likely due to the use of the whole striatum. Nevertheless, such a response, elevated FAAH activ-
ity/local reduction of endocannabinoids, is likely to contribute to disease progression rather
than being an adaptive protective response.
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Conclusions
Our results from SCA-3 transgenic mice confirm that certain elements of the endocannabi-
noid signaling system are altered in the striatum, as previously found in other important brain
structures affected in this type of ataxia (cerebellum, brainstem [17]). Such changes may con-
tribute to the pathogenesis of this condition by aggravating the influence of different neuro-
toxic stimuli in these mice (e.g. excitotoxicity). Hence, a pharmacological manipulation that
corrects the changes in endocannabinoid signaling could be an interesting objective for future
research.
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